Clinical Trial Update: suPAR Michigan M2C2 Heterogeneity Validation Cohort Study

View source ↗

Summary

A completed clinical trial update for the suPAR Michigan M2C2 Heterogeneity Validation Cohort Study evaluating soluble urokinase plasminogen activator receptor …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Snippet

Sponsor: ViroGates A/S | Conditions: COVID-19, Severe Respiratory Distress Syndrome | Status: COMPLETED